Biotech mergers, Cardiovascular systems was to have a public offering earlier this year but things didn’t work out, thus the merger with Replidyne who’s focus is creating treatments for C. difficile bacteria and C. difficile-associated disease (CDAD) while Cardiovascular systems focuses on treatment of occlusive peripheral arterial disease (PAD) with the Diamondback 360 which I remember posting about when it 
received FDA approval. BD
Replidyne and Cardiovascular Systems Sign Merger Agreement Merger to create NASDAQ-listed medical device company focused on developing and commercializing interventional treatment systems for vascular disease Conference call scheduled for Tuesday, November 4, 2008 at 8:30 AM ET LOUISVILLE, Colo. and ST. PAUL, Minn., Nov. 4 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) and Cardiovascular Systems, Inc. (CSI) today announced that they have entered into a definitive merger agreement under which CSI will merge with Replidyne in an all-stock transaction. Under terms of the agreement, Replidyne will issue new shares of its common stock to CSI shareholders whereby former CSI shareholders are expected to own 83 percent of the combined company, and Replidyne shareholders are expected to own 17 percent of the combined company on a fully diluted basis using
0 comments :
Post a Comment